AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Per The Guardian, AstraZeneca is in talks to acquire Bristol Myers Squibb in what would be one of the biggest pharmaceutical deals ever. The tie-up would create a near-four-hundred-billion-dollar pharmaceutical group—the world's fourth-largest drugmaker. AstraZeneca, led by longtime CEO Pascal Soriot, is the UK's second-largest listed company with a market value of a hundred ninety-six billion pounds; Bristol Myers Squibb, headquartered in Princeton and known for its cancer treatments, is valued at a hundred thirty-three billion dollars.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton